DYRK1A and Dravet syndrome: Since current symptomatic treatments for cognitive deficiencies are limited and inefficient, inhibition of DYRK1A function in the brain by small molecules offers a good opportunity for pharmaceutical interference for neurodegeneration associated with AD and DS.